In Chicago, AstraZeneca presented its data at the annual American Society of Clinical Oncology (ASCO) meeting.
MEDI4736 is a type of drug that blocks the tumor formation by inhibiting its activities against the immune system’s defenses. This class of drug is renowned as anti-PDL1 therapies.
AstraZeneca reported the responsiveness in multiple cancer type patients including cutaneous melanoma, non-small lung cancer, gastroesophageal cancer, squamous cell carcinoma of the head and neck, and pancreatic cancer.
In the Phase I clinical trial, in 27 patients, MEDI4736 has produced pronounced effects in the patients of melanoma, non-small cell lung cancer and colorectal cancer. Tumor shrinkage was seen in 19 percent patients and 39 percent has stabilized cancer after a year of treatment.